April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment-resistant hypertension, according to data from two clinical trials presented at the American College of Cardiology (ACC) 61st Annual Scientific Session.

April 4, 2012 — Edwards Lifesciences Corp. reported that longer-term results (? 2 years) from the high-risk Cohort A of the PARTNER Trial – a randomized comparison of patients treated with either surgical aortic valve replacement or the Edwards SAPIEN transcatheter heart valve – were published in The New England Journal of Medicine. The data were concurrently presented at the American College of Cardiology's (ACC) 61st Annual Scientific Session in Chicago.

April 4, 2012 — Medrad (Bayer) recently introduced the Mark 7 Arterion angiographic contrast injection system. The system is much smaller, lighter-weight, more ergonomic and easier to maneuver than previous Medrad injectors. It also is easier to operate than previous models, requiring less time to position and set up. It has a clearly visible and intuitive user interface to guide the user through proper set-up, and highlights the information need to perform injections.

New guidelines for CT-guided biopsies of lung nodules significantly reduce radiation exposure, allowing individuals the benefit of the procedure, which may cut down on overall lung cancer deaths. This research was presented at the Society of Interventional Radiology's (SIR) 37th Annual Scientific Meeting in San Francisco.

Incidences of renal complications, specifically acute renal failure (ARF) and new hemodialysis (HD), continue to increase significantly among Medicare beneficiaries (MB) admitted for percutaneous coronary intervention (PCI). This was according to a study presented last week at the American College of Cardiology’s (ACC) 61st Annual Scientific Session.


A new comparative effectiveness study found older adults with stable coronary disease who underwent coronary artery bypass graft had better long-term survival than those who underwent percutaneous coronary intervention. However, the some experts disagree it was a fair appled-to-apples comparison.

April 3, 2012 – Abiomed Inc. today announced the successful first human use of the Impella cVAD device, a new, percutaneous Impella ventricular assist device (VAD) that provides peak flow of approximately 4 liters of blood per minute. The Impella cVAD is designed to provide temporary circulatory support and reduce the workload of the heart muscle via a minimally invasive, catheter-based pump that is inserted percutaneously in the cardiac catheterization lab, without the need for surgical intervention.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now